Table 1

Characteristics of the study group of 261 patients treated with imatinib and of the historical control group of 204 patients treated with nonimatinib therapies for chronic-phase chronic myelogenous leukemia post-IFN failure

CharacteristicPercentage
CategoryImatinibOtherP
Age (years)≥6034190.0002
SplenomegalyPresent10230.0009
Hemoglobin (g/dl)<1238540.0006
WBC (×109/l)>50925<0.0001
Platelets (×109/l)>45022250.58
% marrow blasts≥51090.92
Peripheral blastsPresent17210.34
% marrow basophils≥420140.11
% peripheral basophils≥711110.94
Cytogenetic clonal evolutionYes9140.18
Prognostic group (Sokal) (20)Low50480.02
Intermediate4131
High921
Duration of chronic phase (months)<1211190.005
12–354248
≥364734
% Philadelphia-positive pretreatment<9023120.01
IFN failureHematologic1433<0.0001
Cytogenetic4835(0.17 for Intolerance vs. other)
Intolerance3831